Table 3.
Range of Borrelia burgdorferi sensu lato (Bb) seroprevalence in five populations from different continents
| Continent | General population | High-risk population | Tick-bitten population | LB-like symptoms population | All |
| America | |||||
| North America | 1.2% (0.0%–5.4%) | 27.8% (4.6%–60.8%) | 30.4% (0.9%–77.2%) | 14.2% (12.4%–16.2%) | 9.4% (2.6%–19.8%) |
| South America | – | 4.6% (1.9%–8.5%) | – | 12.2% (1.8%–29.9%) | 8.7% (3.2%–16.6%) |
| Europe | |||||
| Southern Europe | 4.4% (2.1%–6.8%) | 12.3% (6.4%–16.9%) | – | – | 11.1% (5.2%–18.8%) |
| Western Europe | 7.5% (5.2%–10.1%) | 13.1% (1.7%–32.7%) | 23.2% (6.1%–46.9%) | 47.9% (34.3%–61.6%) | 13.5% (9.5%–18.0%) |
| Northern Europe | 8.6% (5.3%–12.6%) | 9.3% (7.6%–11.1%) | 3.2% (1.6%–5.4%) | 14.3% (5.5%–26.3%) | 7.6% (4.3%–11.7%) |
| Eastern Europe | 4.8% (3.4%–6.5%) | – | 10.7% (7.8%–13.9%) | 35.5% (27.3%–44.1%) | 10.4% (5.3%–16.9%) |
| Central Europe | 10.9% (8.8%–13.2%) | 35.7% (23.0%–49.4%) | 5.5% (2.2%–10.1%) | 11.2% (6.6%–16.8%) | 20.7% (13.8%–28.6%) |
| Asia | |||||
| Eastern Asia | – | 22.5% (14.1%–32.2%) | 71.4% (46.0%–91.2%) | 11.1% (7.5%–15.7%) | 15.9% (6.6%–28.3%) |
| Southern Asia | – | 3.0% (1.6%–4.7%) | – | – | 3.0% (1.6%–4.7%) |
| Western Asia | 5.2% (1.5%–10.9%) | 7.8% (1.6%–18.2%) | 17.1% (9.5%–26.3%) | – | 6.3% (2.3%–12.2%) |
| Caribbean | – | 2.0% (0.6%–4.1%) | – | – | 2.0% (0.6%–4.1%) |
| Oceania | 0.0% (0.0%–21.5%) | – | – | – | 4.1% (0.4%–15.4%) |
| All | 5.7% (4.3%–7.3%) | 14.7% (9.7%–19.5%) | 18.8% (10.1%–29.4%) | 21.3% (14.1%–29.4%) | 11.3% (9.2%–13.6%) |
LB, Lyme borreliosis.